Screener
ADMA Biologics ADMA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense), net | (2,208) | (2,701) | (3,354) | (4,132) |
| INCOME BEFORE INCOME TAXES | 50,237 | 40,097 | 107,365 | 73,546 |
| Provision for income taxes | 12,415 | 5,878 | 24,215 | 12,424 |
| NET INCOME | $$37,822 | $34,219 | $83,150 | 61,122 |
| BASIC EARNINGS PER COMMON SHARE | $$0.17 | $0.14 | $0.36 | 0.26 |
| DILUTED EARNINGS PER COMMON SHARE | $$0.16 | $0.14 | $0.35 | 0.25 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||
| Basic | 228,232,503 | 241,490,715 | 232,136,480 | 238,309,156 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's net income?
- ADMA Biologics (ADMA) reported net income of $37.82M in Q2 2026.
- How has ADMA Biologics's net income changed year-over-year?
- ADMA Biologics's net income increased by 10.5% year-over-year, from $34.22M to $37.82M.
- What is the long-term trend for ADMA Biologics's net income?
- Over 4 years (2021 to 2025), ADMA Biologics's net income has grown at a 19.7% compound annual growth rate (CAGR), from -$71.65M to $146.93M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about ADMA Biologics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude